Skip to main content
logo
Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
15.03
-0.06 (-0.40%)
At close: Aug 13, 2026, 4:00 PM EDT
15.13
+0.10 (0.67%)
Pre-market: Aug 14, 2026, 5:41 AM EDT

Generate Biomedicines Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-250.88-222.97-181.38
Depreciation & Amortization
12.9413.1815.35
Stock-Based Compensation
24.9820.5819.47
Other Adjustments
6.923.210.7
Change in Receivables
0.340.31-0.21
Changes in Accounts Payable
-0.18-2.133.5
Changes in Accrued Expenses
0.0717.374.37
Changes in Unearned Revenue
-26.48-31.8934.54
Changes in Other Operating Activities
-4.671.73-14.08
Operating Cash Flow
-237.02-200.62-117.75
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-7.32-3.51-3.45
Sale of Property, Plant & Equipment
--0.01
Purchases of Investments
-343.98-164.73-282.98
Proceeds from Sale of Investments
182.99285.01228.69
Investing Cash Flow
-168.32116.77-57.73

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Long-Term Debt Repaid
-5.21-8.16-11.12
Net Long-Term Debt Issued (Repaid)
-5.21-8.16-11.12
Issuance of Common Stock
373.381.11.13
Net Common Stock Issued (Repurchased)
373.381.11.13
Issuance of Preferred Stock
021.9796.32
Net Preferred Stock Issued (Repurchased)
021.9796.32
Other Financing Activities
17.913.155
Financing Cash Flow
386.0728.0691.33

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
-19.27-55.79-84.15

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-244.35-204.13-121.2
Free Cash Flow Growth
---
FCF Margin
-922.65%-640.06%-592.39%
Free Cash Flow Per Share
-3.77-6.19-3.78
Levered Free Cash Flow
-299.53-262.94-184.67
Unlevered Free Cash Flow
-287.98-240.15-156.48
SEC Filings: 10-K · 10-Q